Heart failure is a common and debilitating condition with a high mortality.' Reductions in mortality in this condition have been achieved by treatment with vasodilators, in particular the angiotensin converting enzyme (ACE) inhibitors, but there remains a considerable burden of disability and mortality. The other mainstay, diuretic treatment, has never been shown to reduce mortality in heart failure but its ability to relieve life threatening pulmonary oedema and to help relieve fluid retention and dyspnoea in chronic heart failure is not seriously questioned.
It is likely to be increasingly difficult to reduce mortality with newer treatments without specifically targeting the underlying processes leading to left ventricular dysfunction. There remain, however, many unrelieved symptoms in optimally treated patients, with a correspondingly low quality of life. This is a valid area for therapeutic intervention, but one in which objective measurements of benefit have proved difficult to obtain. Therapeutic strategies have also been limited by our poor understanding of the physiological bases of the cardinal symptoms, dyspnoea and fatigue.
Measurement of quality of life in heart failure Fletcher and colleagues have described the requirements of an ideal assessment of the quality of life (table).2 Questionnaires are the most common means of achieving such an assessment, and these can take the form of a general health survey-for example, the Nottingham health profile3-or be specific to the condition under investigation-for example, the Yale scale,4 or the Minnesota living with heart failure questionnaire.5 Quality of
Steps to ensure maximum information from quality of life analyses life assessments have indicated improvement with some treatments, but on an individual patient basis there can be very poor correlation between the change in the quality of life scores and objective improvements in exercise tolerance. Also, different exercise protocols can show different changes with intervention, and there is little consensus as to whether incremental exercise tests or submaximal endurance tests better measure the symptoms limiting patients with chronic heart failure.6
Symptoms limiting exercise in chronic heart failure There is little correlation at rest or during exercise between measures of haemodynamics and either the symptoms limiting exercise in chronic heart failure or the degree of such limitation. Different symptoms may be produced by different forms of exercise tests or by different speeds of incremental exercise tests.7 Even in the same patient there is little correlation between the peak achieved pulmonary artery pressure and which of the two main symptoms limit different types of exercise.7 With ambulatory pulmonary arterial pressure monitoring it has been shown that limiting dyspnoea can occur at dramatically different peak pulmonary arterial pressures during different types of exercise.8 This argues against pulmonary arterial haemodynamics being the main determinant of this symptom.
The inability of haemodynamics to explain the generation of symptoms in chronic heart failure calls into question the dependence that has traditionally been placed on haemodynamic screens for potential agents of heart failure. If non-haemodynamic peripheral factors both limit exercise and are responsible for generation of symptoms, then other nonhaemodynamic modes of action may be effective for relief of symptoms in chronic heart failure. Muscle fatigue in chronic heart failure Muscle fatigue can arise due to alterations in the supply of oxygen to exercising muscle or to a change in the muscle itself. Skeletal muscle can be abnormal in terms of total mass, structure, or metabolic or contractile function. Although restrictions in peak blood flow to exercising muscle have been shown in heart failure,9 10 to a excessive sensation of breathlessness and an exaggerated ventilatory response in heart failure.20 It has been argued that the increased ventilation seen during exercise in patients with heart failure must indicate the presence h there is of wasted ventilation in the form of dead total peak space ventilation because there is no substanreduced, tial fall in arterial blood concentrations of ,ut muscle CO2. There is, however, often a modest fall in aphy) the arterial CO, during exercise, and arterial 02 rgests that rarely if ever falls in stable heart failure, so the )w may be factor that initiates and maintains the of muscle. increased ventilatory response is not obvious. .le histol-Something other than CO2 retention or rine activi-hypoxia must be driving both the sensation of handling'4 breathlessness and the resultant exaggerated heart fail-ventilatory response. We have studied this Lny one of response by looking at the ventilatory equivaexertional lent for CO2 (the slope between ventilation ilure, and and the rate of CO2 production) during exerrs is oper-cise.21 This slope is increased in heart failure We have and the increase in slope correlates well with correlates the severity of heart failure as assessed by peak heart fail-02 consumption (fig 2) . me,16 sugIt is not known which of several indepenalterations dent and complementary ventilatory control of skeletal systems can account for the increased ventilation in heart failure, but early lactic acid release and acidosis, potassium release, respiratory muscle fatigue, non-asthmatic bronchial constriction, and a muscle ergore--0.32 flex22 have all been proposed. Circulating factors including lactate and acidosis do not seem necessary for this response and differences in potassium release do not seem to account for the altered response in heart fail-U* ure (unpublished observations). The frequent coexistence of dyspnoea and fatigue and the delay in resolution of dyspnoea after haemodynamic improvement raise the possibility that structural abnormalities of skeletal muscle may be involved in the genera- group.bmj.com on June 15, 2017 -Published by http://heart.bmj.com/ Downloaded from those seen in skeletal muscle. Early respiratory muscle fatigue and histological changes in the diaphragm23 have been seen in chronic heart failure. An alternative explanation is that skeletal muscle signals contribute directly to the perception of both muscle fatigue and dyspnoea, not only through the excessive release of blood borne metabolic factors, but possibly also through an exaggerated neural signal from the muscle.
Mechanisms of skeletal myopathy in chronic heart failure The cause of the changes in skeletal muscle in chronic heart failure is not clear, but research on the beneficial effects of exercise training on skeletal muscle function in heart failure2426 has suggested that inactivity may play a part. Metabolic or hormonal derangements that favour catabolism over anabolism may also contribute to the myopathy. Possibilities include the release of tumour necrosis factor, abnormalities in the handling of intracellular thyroid hormone, and insulin resistance, as well as intestinal malabsorption. There is little agreement as to whether chronically impaired skeletal muscle flow is an important cause of the myopathy of heart failure, but the dissimilarity between the muscle changes of heart failure and the increased oxidative capacity seen in patients with peripheral vascular insufficiency make this unlikely. Similar changes are by contrast seen in chronic lung disease suggesting that many chronic disease processes involving prolonged inactivity may lead to a similar syndrome.27 The cachexia of neoplastic disease has some similarities with cardiac cachexia, and this syndrome can also be associated with unexplained dyspnoea.
Importance of skeletal myopathy in heart failure: the skeletal muscle ergoreflex Small myelinated and unmyelinated fibres arise from poorly characterised work sensitive receptors within skeletal muscle.28 These fibres travel in the lateral spinothalamic tract and have been shown to mediate an ergoreflex effect constituting an increase in sympathetic outflow producing vasoconstriction in distant vascular beds and possibly a small increase in heart rate.28 They are sensitive to the metabolic state of the muscle but not to ischaemia alone; rather they are work sensors. Excess of intramuscular potassium may stimulate their activation. We have recently-shown that these ergoreceptors are active in patients with-heart failure and that they also substantially contribute to the ventilatory response to exercise in both normal people and patients with heart failure.22 Also they are ideal candidate receptors for the perception of muscular fatigue and that componet of dyspnoea that cannot be explained by circulating metabolites.
Although one short report suggested that the sympathetic nervous response to ergoreceptor activation in heart failure was blunted, the vastly different baseline levels of sympathetic tone in the two patient groups in this paper made it difficult to interpret the incremental effect of ergoreflex activation. 29 The muscle ergoreceptors have the properties necessary to link the abnormal skeletal muscle function of chronic heart failure to the fatigue, dyspnoea, hyperpnoea, and sympathoexcitation characteristic of this condition.
The muscle hypothesis of chronic heart failure We propose that abnormal skeletal muscle in chronic heart failure is a central abnormality that can account for much of the pathophysiology and symptoms of the condition. This hypothesis proposes another cycle of deterioration similar to those of neuroendocrine activation. A reduction in left ventricular function sets in motion a series of metabolic events that lead to wasting of skeletal muscle and resultant abnormalities of muscular metabolism and function. In response to early metabolic distress in exercising muscle an exaggerated ergoreflex activation occurs that is perceived by the patient as both muscle fatigue and dyspnoea. This leads to excessive reflex sympathetic vasoconstrictor drive to non-exercising muscle beds and an excessive ventilatory response to exercise. Resolution of these symptoms and the exaggerated reflex responses would depend on resolution of the abnormal function of skeletal muscle, and would, therefore, be delayed after haemodynamic correction and would be most noticeable in treatments associated with a specific improvement in muscle function or exercise responses. Figure 1 shows the proposed sequence of events.
Consequences of a muscle hypothesis for the generation of symptoms in heart failure Valid areas for investigation (and perhaps intervention) exist to prevent the cycle of events described in this hypothesis. One aspect of this theory is that the skeletal myopathy, by exaggerating the sympathetic nervous responses to exercise, may actually contribute to the progression of the disease process through an exaggeration of peripheral vasoconstriction and hence the afterload that develops and through the direct myotoxic effects of prolonged sympathoexcitation. Ventricular remodelling and the propensity to ventricular arrhythmias are both thought to be partly a result of such excessive and prolonged sympathetic activation. The precise mechanism of the persistent sympathoexcitation of chronic heart failure has never been established. The arterial baroreflex loop is not an ideal explanation because the gain of this reflex is known to be dramatically impaired in heart failure,30 31 
